Found 297 Results
Page 1 of 30
Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors Paris (France), […]
06/30/2022
All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]
06/16/2022
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
04/28/2022
Watch the interview (in French)
04/20/2022
Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]
04/07/2022
Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]
04/06/2022
AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]
03/31/2022
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Paris (France), March 9, 2022 – 7:00 […]
03/09/2022
Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]
01/13/2022
Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]
01/03/2022
Page 1 of 30
